Next Generation Genome Editing Market Size, Share & Trends Analysis Distribution by Type of Gene Editing Technique (Recombinase-Based Editing, Prime Genome Editing, Bridge Editing, Base Editing, Retron Library Recombineering (RLR), Transposon-Based Systems, Homology-Directed Repair (HDR)), Application Area, Type of End User and Segment Forecasts, 2024-2031
Segmentation of Next Generation Genome Editing Market -
Next Generation Genome Editing Market by Type of Gene Editing Technique -
- Recombinase-Based Editing
- Prime Genome Editing
- Bridge Editing
- Base Editing
- Retron Library Recombineering (RLR)
- Transposon-Based Systems
- Homology-Directed Repair (HDR)
- Other emerging technologies
Next Generation Genome Editing Market by Application Area -
- Drug Discovery and Development
- Diagnostics
Next Generation Genome Editing Market by Type of End User -
- Biotechnology Companies
- Academic Institutions
- Government Laboratories
- Contract Research Organizations
Next Generation Genome Editing Market by Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next Generation Genome Editing Market Snapshot
Chapter 4. Global Next Generation Genome Editing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Gene Editing Technique Estimates & Trend Analysis
5.1. By Type of Gene Editing Technique & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of Gene Editing Technique:
5.2.1. Recombinase-Based Editing
5.2.2. Prime Genome Editing
5.2.3. Bridge Editing
5.2.4. Base Editing
5.2.5. Retron Library Recombineering (RLR)
5.2.6. Transposon-Based Systems
5.2.7. Homology-Directed Repair (HDR)
5.2.8. Other emerging technologies
Chapter 6. Market Segmentation 2: By Application Area Estimates & Trend Analysis
6.1. By Application Area & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Application Area:
6.2.1. Drug Discovery and Development
6.2.2. Diagnostics
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. By End User & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End User:
7.2.1. Biotechnology Companies
7.2.2. Academic Institutions
7.2.3. Government Laboratories
7.2.4. Contract Research Organizations
Chapter 8. Next Generation Genome Editing Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.1.2. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.1.3. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.1.4. North America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.2.2. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.2.3. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.2.4. Europe Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.3.2. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.3.3. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.3.4. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Asia Pacific Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.4.2. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.4.3. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.4.4. Latin America Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Type of Gene Editing Technique, 2024-2031
8.5.2. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2024-2031
8.5.3. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.5.4. Middle East & Africa Next Generation Genome Editing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Addgene
9.2.2. Beam Therapeutics
9.2.3. Bio Palette Co., Ltd
9.2.4. Caribou Biosciences
9.2.5. Cellectis
9.2.6. Creative Biogene
9.2.7. CRISPR Therapeutics.
9.2.8. Danaher Corporation
9.2.9. EdiGene, Inc.
9.2.10. Editas Medicine
9.2.11. ElevateBio
9.2.12. GenKOre
9.2.13. GenScript
9.2.14. Horizon Discovery Ltd.
9.2.15. Inscripta, Inc
9.2.16. Integrated DNA Technologies (IDT)
9.2.17. Intellia Therapeutics
9.2.18. KromaTiD, Inc
9.2.19. Maravai LifeSciences
9.2.20. Merck KGaA
9.2.21. Pairwise
9.2.22. Precision BioSciences
9.2.23. ProQR Therapeutics
9.2.24. QI-Biodesign
9.2.25. Recombinetics
9.2.26. Revvity
9.2.27. Sangamo Therapeutics, Inc.
9.2.28. Scribe Therapeutics
9.2.29. Shape TX
9.2.30. Synthego
9.2.31. Synthorx (part of Sanofi)
9.2.32. Other prominent players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Next Generation Genome Editing Market Size is predicted to develop with a CAGR of 21.8% during the forecast period for 2024-2031.
Addgene, Beam Therapeutics, Bio Palette Co., Ltd, Caribou Biosciences, Cellectis, Creative Biogene, CRISPR Therapeutics, Danaher Corporation, EdiGene,